Announcement on Resignation of Senior Management Members
Filed with SSE · · 2 pages · Chinese
Shanghai Pharmaceuticals Holding Co. Ltd. on 6ix
Earlier from Shanghai Pharmaceuticals
- Indicative Announcement on Changes in Shareholder's Equity
- Announcement on Nicorandil Tablet Passing Generic Drug Consistency Evaluation
- Announcement on Shareholding Increase Plan for the Controlling Shareholder
- Announcement on Obtaining Philippine Drug Registration Certificate for Aripiprazole Tablets
- Announcement on Diprophylline Injection Passing Generic Drug Consistency Evaluation
Later from Shanghai Pharmaceuticals
- Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan and in Q3 2025
- Announcement on Obtainment of U.S. FDA Approval for Doxycycline Capsules
- Announcement on the Subsidiary Becoming the Marketing Authorization Holder of Amisulpride Orally Disintegrating Tablets
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Resolutions of the 25th Meeting of the 8th Board of Directors
Follow Shanghai Pharmaceuticals into a list and get an email when it puts out news.
Follow Shanghai Pharmaceuticals